Introduction {#sec1-1}
============

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for more than 80% of all lung cancer cases. About 60% of NSCLC cases present with metastatic disease and 5-year survival remains poor.\[[@ref1]\] Standard of care for stage four, driver mutation-negative NSCLC till now remained platinum doublet therapy with 1-year median survival.\[[@ref2]\] After disease progression, few treatment options were available, i.e., docetaxel and pemetrexed (pemetrexed for the treatment of only adenocarcinoma). There was an unmet need for second-line treatment options that will improve overall survival (OS) with a better side-effect profile.

In a multicohort Phase 1 study involving previously untreated patients with NSCLC (CheckMate 012), 12 durable responses were seen in patients who received nivolumab. Median progression-free survival (PFS) was 10.6 months, and response rates were 50%. Clinical activity was not only seen in patients with increasing Programmed Death Ligand-1 (PDL-1) levels but also with a low-PDL-1 expression level or with no PDL-1 expression.

In two pivotal CheckMate trials,\[[@ref3][@ref4]\] comparing nivolumab to docetaxel in the second-line setting, nivolumab resulted in longer OS in both squamous and nonsquamous advanced NSCLC. Nivolumab was the first checkpoint inhibitor that was compared to docetaxel and approved as second-line option for both squamous and adenocarcinoma \[[Table 1](#T1){ref-type="table"}\].

###### 

Nivolumab clinical trials in second-line treatment for Stage 4 lung cancer

  Study                Line of Treatment   Agent                    Trial Phase   RR         Median OS     Median PFS
  -------------------- ------------------- ------------------------ ------------- ---------- ------------- ------------
  Checkmate 017. (3)   Second Line         Nivolumab vs Docetaxel   III           20 vs 9    9.2 vs 6      3.5 vs 2.8
  Checkmate 057. (4)   Second Line         Nivolumab vs Docetaxel   III           19 vs 12   12.2 vs 9.4   2.3 vs 4.2

RR=Response rate, OS=Overall survival, PFS=Progression-free survival

After the two pivotal CheckMate trials,\[[@ref3][@ref4]\] nivolumab became standard of care in second-line setting for both histological subtypes (adenocarcinoma and squamous cell carcinoma) irrespective of PDL-1 status and showed a survival benefit in previously treated patients.

In clinical trials conducted so far, \<30% of patients benefited from nivolumab. Therefore, the identification of biomarker for predicting nivolumab efficacy is crucial.\[[@ref5][@ref6][@ref7][@ref8]\]

Materials and Methods {#sec1-2}
=====================

This is a retrospective study of 11 NSCLC patients, who progressed on chemotherapy, treated with nivolumab in our center from April 2016 to December 2018.

Informed consent was obtained from all 11 patients involved in the study.

Eligible patients included, histologically proven NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status of zero, one, or two, age 18 years and above, availability of pretreatment tumor specimen, adequate end organ function, at least one prior platinum-based therapy. Patients who received a minimum of six doses of nivolumab were eligible.

Criteria for exclusion were autoimmune disease, symptomatic interstitial lung disease, systemic immunosuppression, or prior therapy with T-cell co-stimulation or checkpoint-targeted agents.

The PFS was calculated from the 1^st^ day of the administration of nivolumab until any progression based on imaging available (local or distant).

The OS was calculated from the 1^st^ day of nivolumab administration until death.

Tumor response was assessed using the the data was analyzed using IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.

Results {#sec1-3}
=======

Eleven previously treated patients with chemotherapy, started on nivolumab from April 2016 to December 2018, were retrospectively studied and analyzed. The median age of patients was 58 years. Eight (72.73%) of the eleven patients were male. Seven (63.64%) of the patients were current or former smokers. Majority of patients had nonsquamous histology; 7 (63.64%) adenocarcinoma and 4 (36.36%) squamous cell carcinoma.

All of the patients included in the study received platinum-based therapy before immunotherapy. Five (45.46%) patients received one prior therapy, 3 (27.27%) received two prior therapies, and 3 (27.27%) received three prior therapies.

Four (36.36%) of the patients had brain metastasis.

Two (18.18%) of the patients were more than 70 years of age \[[Table 2](#T2){ref-type="table"}\].

###### 

Patient characteristics

  Patients     Age   Sex   History of smoking   Histology   Metastasis to brain   Number of prior lines of therapy   Radiotherapy prior to immunotherapy   Time interval between last therapy and start of immunotherapy (days)   ORR
  ------------ ----- ----- -------------------- ----------- --------------------- ---------------------------------- ------------------------------------- ---------------------------------------------------------------------- -----
  Patient-1    74    M     YES                  ADENO       NO                    2                                  NO                                    60                                                                     CR
  Patient-2    73    M     YES                  SCC         YES                   2                                  YES                                   30                                                                     PD
  Patient-3    58    M     YES                  SCC         YES                   1                                  NO                                    30                                                                     PD
  Patient-4    62    F     NO                   ADENO       NO                    1                                  NO                                    60                                                                     PD
  Patient-5    65    M     YES                  ADENO       NO                    1                                  YES                                   5                                                                      PD
  Patient-6    56    M     YES                  ADENO       NO                    3                                  NO                                    15                                                                     PD
  Patient-7    52    M     NO                   ADENO       YES                   3                                  YES                                   135                                                                    PR
  Patient-8    40    F     NO                   SCC         YES                   1                                  YES                                   110                                                                    SD
  Patient-9    50    F     NO                   ADENO       NO                    1                                  NO                                    30                                                                     PR
  Patient-10   67    M     YES                  SCC         NO                    2                                  YES                                   285                                                                    SD
  Patient-11   42    M     YES                  ADENO       NO                    3                                  YES                                   20                                                                     SD

ADENO=Adenocarcinoma, SCC=Squamous cell carcinoma, ORR=Overall response rates, M=Male, F=Female, CR=Complete response, PD=Progressive disease, PR=Partial response, SD=Stable disease

All patients included in the analysis received at least six cycles of nivolumab at the standard dose of 3 mg/kg of body weight every 2 weeks. The median number of cycles of nivolumab administered was ten (range, 6--21).

At the time of analysis, the median PFS was 8 months (95% confidence interval \[CI\], 1.52--14.47) and median OS was 15 months (95% CI, 6.9--23.09) \[Figure [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\].

![Kaplan--Meier curves. (a) Progression-free survival; (b) overall survival (CI=Confidence Interval)](SAJC-9-50-g001){#F1}

Response rates {#sec2-1}
--------------

Among 11 patients studied, 1 (9.09%) had complete response (CR), 2 (18.18%) partial response, 3 (27.27%) stable disease, and 5 (45.45%) progressive disease \[[Table 3](#T3){ref-type="table"}\].

###### 

Overall response rates

  Items                 Data (number of patients)   Percentage
  --------------------- --------------------------- ------------
  Objective response    6                           54.54
  Complete response     1                           9.09
  Partial response      2                           18.18
  Stable disease        3                           27.27
  Progressive disease   5                           45.45

Adverse events {#sec2-2}
--------------

Pruritus was the most common side effect, seen in 8 (72.73%) of 11 patients. Fatigue and hypothyroidism were seen in 6 of 11 patients (54.55%). Two of 11 patients (18.18%) developed Grade 3--4 pneumonitis. Both these patients, despite the prolonged hospital stay and high-dose corticosteroids, did not recover from Grade 3--4 pneumonitis \[[Table 4](#T4){ref-type="table"}\].

###### 

Adverse events

  Adverse Events   Grade 1-2, *n* (%)   Grade 3-4, *n* (%)
  ---------------- -------------------- --------------------
  Pneumonitis                           2 (18.18)
  Pruritis/rash    8 (72.73)            
  Hypothyroidism   6 (54.55)            
  Renal toxicity   1 (9.09)             
  Nausea           1 (9.09)             
  Diarrhea         1 (9.09)             
  Fatigue          6 (54.55)            
  Vomiting         1 (9.09)             

Discussion {#sec1-4}
==========

Limited progress, related to second-line therapy in NSCLC, has been made since the approval of docetaxel as second-line chemotherapy for metastatic lung cancer. Despite the increased number of treatment options for NSCLC, survival remains poor. PDL-1 inhibitors have emerged as the new standard of care for the second-line treatment of NSCLC. In addition, pembrolizumab has been approved for patients with metastatic NSCLC, having PDL-1 expression of more than or equal to 50%.

It is important to evaluate the benefit shown in clinical trials to the lung cancer population in real-world settings.

Both squamous and nonsquamous histological subtypes of NSCLC were analyzed in two separate clinical trials. In CheckMate 017, median PFS was 3.5 months with nivolumab and 2.8 months with docetaxel, and median OS was 9.2 months with nivolumab versus 6.2 months with docetaxel. There were higher response rates (20 vs. 9%) and longer duration of response (25.2 vs. 8.4 months) favoring nivolumab versus docetaxel. In CheckMate 057, higher response rates were seen with nivolumab (19 vs. 12%). The median OS was higher with nivolumab (12.2 vs. 9.5), but median PFS was higher with docetaxel as compared to nivolumab (4.2 vs. 2.3 months).

In our study, the response was observed in 6 (54.54%) patients, 1 (9.09%) patient had CR, 2 (18.18%) had a partial response, and 3 (27.27%) had stable disease. Progressive disease was seen in 5 (45.45%) patients.

Treatment with nivolumab was well tolerated, and generally, side effects were Grade 1 and Grade 2, except two patients who developed Grade 3/4 pneumonitis.

The median PFS was 8 months (95% CI, 1.52--14.47) and median OS was 15 months (95% CI, 6.9--23.09) in our study, which was more than the CheckMate studies, probably because all patients in our study had good performance status (ECOG 1), sample size was small, unselected nonclinical trial population and was a retrospective study.

Conclusion {#sec1-5}
==========

Nivolumab proved its meaningful survival benefit in clinical practice since the effectiveness appears to be higher in this unselected nonclinical trial population as compared to the results of the clinical trials. Although our sample size was small, our data support the use of nivolumab as a new treatment option for patients of stage four NSCLC.
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